세계의 암 치료제 시장 : 재발 및 전이 부문에 대한 강조

The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.

The global market for lung cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $16.2 billion in 2024 to reach $29.0 billion by 2029, at a CAGR of 12.4% from 2024 to 2029.

The global market for breast cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $13.7 billion in 2024 to reach $23.6 billion by 2029, at a CAGR of 11.4% from 2024 to 2029.

Report Scope

Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.

Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.

Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:

• Lung.
• Breast.
• Liver.
• Stomach.
• Prostate.
• Colorectal.
• Gastric.
• Cervical.
• Bladder.
• Kidney.
• Ovarian.
• Lymphoma.
• Multiple myeloma.
• Brain tumors.
• Thyroid.
• Uterine.

Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.

For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.

Report Includes

• 51 data tables and 83 additional tables
• An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
• Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
• A look at the factors driving the market's growth and constraints
• Insight into the industry value chain analysis, providing a study of the intermediaries involved
• Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
• Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
• Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
• Identification of the fastest-growing applications and technologies, and a review of current market trends
• Discussion of the industry's ESG challenges and practices
• Review of the current market status, technology issues, industry value chain, Porter's Five Forces, competitive landscape, R&D activity and patent analysis
• Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
• Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
• Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Metastatic or Recurrent Cancer Treatment Types
• Surgery
• Chemotherapy
• Radiotherapy
• Targeted Therapy
• Cancer Immunotherapies
• Oncolytic Virotherapy
• Antibody-Drug Conjugates
• Porter's Five Forces Analysis in the Oncology Market
• Potential of New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Rivalry: High

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Robust Approval of Oncology Drugs
• Technological Advances in Cancer Treatments
• Increasing Incidence of Cancer Disease
• Market Restraints
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals
• Market Opportunities
• Incorporation of Artificial Intelligence in Oncology
• Promising Drugs in the Late Stage of the Pipeline

Chapter 4 Regulatory Landscape

• The U.S. Approval Process
• FDA Regulatory Considerations for Oncology Drug Development
• European Union Approval Process
• Current Situation in E.U. Approval Process
• Japanese Approval Process

Chapter 5 Emerging Trends and Pipeline Analysis

• Emerging Technologies
• Personalized Cancer Vaccines
• Test to Identify 18 Early-Stage Cancers
• CAR T-Cell Therapy
• Artificial Intelligence
• Tablet to Cut Breast Cancer Risk
• Nanoparticles
• Pressurized Intraperitoneal Aerosol Chemotherapy
• Cervical Cancer Treatment Breakthrough
• New Developments
• Biosimilar Approvals
• Pipeline Analysis
• Clinical Trial Analysis
• Patent Analysis
• Key Takeaways

Chapter 6 Supply Chain Analysis

• Overview
• Research and Development
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers
• Cancer Drug Shortage
• Costs
• Manufacturing Complexity
• Geographic Concentration
• Quality

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Cancer Type
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Liver Cancer
• Cervix Cancer
• Bladder Cancer
• Kidney Cancer
• Pancreatic Cancer
• Ovarian Cancer
• All Other Cancers
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Competitive Intelligence

• Overview
• Blockbuster Oncology Pharmaceutical Brands
• Global Market Shares of Leading Companies

Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective

• Role of ESG in the Pharma Industry
• ESG Performance Analysis
• Environmental Factors
• Social Issues
• Governance Factors
• ESG Risk Ratings
• Conclusion

Chapter 10 Appendix

• Methodology
• Emerging Start-ups/Market Disruptors
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.